Key Takeaways
- Margins hit by Chinese imports, volumes held: Volumes rose over 15% across products, but margins compressed sharply because of competition from China in two or three specific products, especially Acetonitrile and ethylamines.
- Ethylamines: the pain is priced in, the capacity is in place: A new 100-tons-per-day ethylamine plant was commissioned in October, and management argues margins can only improve from here because no new capacity is coming and the market is growing.
- Acetonitrile remains the open wound: Domestic competitors have exited at current prices, but Chinese dumping continues; the company is on the verge of filing for anti-dumping duty, a process that takes about six months.
- New products are the long-term bet, but details are scarce: Management declined to name the new derivatives and specialties in the pipeline, saying only that they could contribute 15–20% of sales within five years of launch and that the company may be among the top 2–3 global producers.
- What to watch next quarter: Whether the anti-dumping application for Acetonitrile is actually filed, any sign that Chinese competitors are rationalizing capacity, and whether the agrochemical and rubber-chemical end-markets deliver the turnaround their customers are signaling.
Margin Pressure: Where It Hurts
- Two products, one story: The margin contraction is concentrated in ethylamines and Acetonitrile; methylamines and smaller derivatives are performing well and keeping the company afloat.
- Ethylamines: a cost-pass-through problem: Ethanol, the key raw material, rose from ₹30 to ₹55 over 2.5–3 years, and not all of that increase could be passed on, especially once a domestic competitor added capacity and pushed out imports over the last six months. Alkyl retained market share but sacrificed margins to do so.
- Acetonitrile: Chinese dumping: Competition from across the border is the primary driver; domestic competitors have backed out of the ACN market because prices are too low for them, and they will return only once margins normalize.
- The historical lens: Management frames the record-profit period (₹400 crores PBT) as abnormal and the current low margins as equally not the norm; the sustainable "norm" lies somewhere in between. The company goes through such difficult 1–2-year periods roughly every decade and emerges stronger.
Kirat Patel: "As you can see, this half year, especially the second quarter has been a little difficult for us in terms of margins, and this is largely due to some domestic competition and majorly a competition from across the border from China in two or three specific products."
Ethylamines: Capacity In, Waiting for the Cycle
- New plant commissioned: The 100-tons-per-day ethylamine plant started up in October, adding 30,000–35,000 tonnes per annum of capacity. Most expenses are already incurred, with only minor modifications remaining.
- Utilization strategy: In the initial phase, the company does not intend to run at full capacity; it will operate at a lower, optimal level and use swing campaigns to match market demand.
- The margin outlook: Management sees only upside from here because no new capacity is coming onstream and the market is growing; the company has already invested and does not need to spend more for capacity increases. The timing of margin recovery to levels seen 2.5 years ago, however, is unpredictable.
- The hindsight admission: The ethyl plant could have been delayed by a year or two given the current scenario, but that was difficult to forecast. Over a 3–4-year horizon, management believes it will look like a great investment.
Kirat Patel: "Yes, as somebody said, hindsight is always 20-20. We could have delayed the ethyl plant for another year or two given the scenario just now, but it's very difficult to predict, you know."
Acetonitrile: The Anti-Dumping Timeline
- The filing is imminent: The company is in the process of putting papers together and is on the verge of applying for anti-dumping duty on Chinese imports. The process takes about six months from filing.
- Capacity utilization at risk: In the second half, the company hopes to maintain 60–65% capacity utilization if Chinese producers show restraint; if prices become more aggressive, there could be further impact.
- Product quality as a moat: The company has successfully developed all the purity grades required by the pharma and electronics industries, not just agrochemical grades, which broadens the addressable market once pricing normalizes.
- Domestic competitors have folded: Local players have exited the ACN market at current price levels; they will re-enter only when margins recover, which means Alkyl is effectively absorbing the market pain alone for now.
Volume Growth & End-Market Health
- Secular volume growth of over 15%: The increase was broad-based across products, roughly 10% in some and 20% in others. Market share in most products remained steady or increased.
- Methylamines: the steady performer: Unlike ethylamines, methylamines face no overcapacity and no Chinese competition; all players have been able to pass on raw material increases. DMA (di-methylamine) is perpetually in short supply while mono is in excess, a structural dynamic that supports pricing.
- Pharma: destocking over: The destocking that weighed on pharma demand last year has ended, and the sector is now growing.
- Agro and rubber chemicals: green shoots: Customers in both segments are talking about seeing light at the end of the tunnel and expect a turnaround.
- DEK commercialized but facing headwinds: The product has been launched in the market, but imports and a tight market are creating difficulties; management remains fairly confident it will meet sales and capacity targets over time.
New Products: The Next Leg of Growth
- Pipeline in motion: New products are at various stages of R&D, engineering, procurement, and in one case, equipment erection. Management will discuss them only after commercial launch, consistent with a long-standing principle.
- Scale of ambition: Within five years of launch, these new products are targeted to comprise at least 15–20% of overall sales, even as the existing business continues to grow. The company may be among the top 2–3 producers globally for some of these specialized products.
- End-market mix: The new products target both agrochemical and pharma applications, plus some other uses, and will serve a mix of domestic (import substitution) and global markets.
- CAPEX allocation shifts: Growth CAPEX will be directed toward the new product business, not the current amines business. Over time, the portfolio mix is expected to evolve from 100% amines toward a 50/25/25 split across amines, derivatives, and specialties.
- Core amines remain the foundation: Amines will stay the core business for some time, even as proportions shift.
Kirat Patel: "That's the hope. That's the logic and the strategy. But of course, reality sometimes goes differently, but I think that is, you are right. That's the way we would like to go, and that's how we have planned these products."
Cost-Side Levers & Operational Improvements
- Power and fuel costs easing: Coal prices have come down from their peaks, directly benefiting the company. New turbines running on extracted steam have been commissioned at both Dahej and Kurkumbh, and solar power is being wheeled into both plants.
- New boiler online: A technologically superior boiler was commissioned in September for the ethyl plant, expected to deliver marginal efficiency improvements.
- Solar plant imminent: The solar plant will be commissioned within days of the call date (November 8, 2023).
- Combined energy savings unclear: When asked for the expected overall power cost savings from these initiatives (against a ₹60 crore investment), management did not have a figure ready and offered a rough guess of ₹10–20 crores, promising to work it out and revert offline.
- Other expenditure jump explained: The sequential rise from ₹84 crores to ₹89.5 crores was driven by higher CSR expenses in Q2, not by one-off plant startup costs; the ethylamine plant started at the very end of September with negligible costs that were capitalized.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Anti-dumping filing for Acetonitrile | Papers being assembled; company "on the verge" of applying | Process takes ~6 months from filing |
| Ethylamine margin direction | "Can only improve" because no new capacity is coming and market is growing | Recovery timeline unpredictable; could be 6 months, 1 year, or longer |
| ACN capacity utilization | Hope to maintain 60–65% if Chinese show restraint | Second half of FY24 |
| New product launch | At various stages of R&D through equipment erection | "Probably next year or the year after" |
| New product sales contribution | At least 15–20% of overall sales | Within 5 years of launch |
| FY25 vs FY24 | Hopeful that FY25 will be a better year | FY25 |
| PBT surpassing FY20–21 peak | Could take 3 years, or next year if margins widen | No firm timeline |
Key Metrics
| Metric | Q2 FY24 |
|---|---|
| Revenue | Not stated |
| Operating margin | Not stated |
| Net profit / PBT | ₹100 cr PBT in H1 FY24 |
| Volume growth | Over 15% in H1 FY24 across various products |
| Ethylamines domestic demand | 25,000–30,000 tons, growing 5–7% annually |
| Ethylamines market share | ~70% for Alkyl Amines, ~25% competitor, ~5% imports |
| New ethylamines plant capacity | 30,000–35,000 tons per annum (100 tons/day); first phase 24,000 tons commissioned in October |
| Acetonitrile CIF price | $1.4 per Kg, near historical lows |
| Acetonitrile capacity utilization | 60–65% in H1 FY24 |
| Methylamines market condition | Balanced; raw material cost increases passed on; no Chinese competition |
| Sales mix | ~50% amines, ~25% derivatives, ~25% specialties |
| Total plant capacity | ~2 lakh tons per annum across 14 plants |
| Overall capacity utilization | 50–55% currently |
| Expected FY24 production volume | ~1 lakh to 1,10,000 tons |
| CAPEX incurred in H1 FY24 | ~₹85 cr, mainly on new ethylamines plant |
| CAPEX planned for H2 FY24 | ~₹50 cr, major part for solar plant |
| CAPEX planned for FY25 | ~₹150 cr (not yet firm) |
| Anti-dumping duty targeted on ACN | 15–20% higher than current prices |
| Energy cost savings from new projects | At least ₹10–20 cr per annum at current prices (per management estimate) |
| Coal price | ~₹11,000 per ton, down from peak of ₹15,000–16,000 |
| Other expenditure | ₹89.5 cr in Q2 FY24, up from ₹84 cr in Q1; increase mainly due to CSR expenses |